A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy

• Published in: PloS one Vol. 11; no. 9; p. e0160437
• Main Authors: Yang, Yue, Ma, Ye-ping, Chen, Da-peng, Zhuo, Li, Li, Wen-ge
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 06.09.2016; Public Library of Science (PLoS)
• Subjects: Analogs; Antigens; Antiretroviral agents; Antiviral agents; Antiviral Agents - therapeutic use; Antiviral drugs; Bias; Biology and Life Sciences; Care and treatment; Chronic infection; Drugs; Gastroenterology; Glomerulonephritis, Membranous - drug therapy; Glomerulonephritis, Membranous - etiology; Glomerulonephritis, Membranous - virology; Hepatitis; Hepatitis B; Hepatitis B - complications; Hepatitis B - drug therapy; Hepatitis B - virology; Hepatitis B e antigen; Hepatitis B e Antigens - drug effects; Hepatitis B virus; Hepatitis B virus - drug effects; Hepatitis B virus - pathogenicity; Humans; Infections; Interferon; Interferons - therapeutic use; Kidneys; Liver; Medicine and Health Sciences; Membranous nephropathy; Meta-analysis; Nephrology; Nephropathy; Nucleoside analogs; Nucleosides; Nucleosides - therapeutic use; Patients; Physical Sciences; Proteinuria; Remission; Research and Analysis Methods; Risk assessment; Studies; Systematic review; Therapy; Viruses
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0160437

Hepatitis B virus-associated membranous nephropathy (HBV-MN) is the most common renal extra-hepatic manifestation in patients with chronic HBV infection. In September 2015, we searched the MEDLINE, EMBASE, and CENTRAL databases, and the reference lists of retrieved articles, to identify relevant studies. Descriptions of antiviral drugs used to treat HBV-MN were included in our review. Two authors independently screened all relevant articles, extracted data, and assessed the risk of bias. Nine hundred and fifty-four papers have been considered after electronic and manual searching, only five relevant studies were identified. Complete remission (OR = 26.87, 95% CI: 8.06 to 89.52), total remission (OR = 10.31, 95% CI: 3.59 to 29.63) of proteinuria and HBeAg clearance (OR = 20.91, 95% CI: 6.90 to 63.39) increased significantly after antiviral therapy. No significant differences were seen between interferon and nucleoside analog treatments. Our study found that antiviral therapy was an effective treatment in HBV-MN patients; interferon and nucleoside analogs were equally effective at causing proteinuria remission and HBeAg clearance.